Introduction
The process of leukocyte extravasation is crucial to host survival, such that following application of an inflammatory or infectious stimulus, a co-ordinated series of cellular and vascular responses are set in train: in this scenario, the blood-borne polymorphonuclear leukocyte (PMN) represents the first line of defence in innate immunity as it is the first cell type to rapidly extravasate 1 . PMN trafficking is tightly regulated, such that pro-and antiinflammatory mediators operate in concert to promote and control the spatio-temporal aspects of PMN extravasation 2 . The full dynamics of this process have yet to be addressed but it is now well accepted that besides adhesion molecules, cytokines and chemokines, acting together to direct leukocyte subsets out of the blood stream, there are counter-regulatory mediators that act as stop signals to inhibit PMN extravastion 3 .
Annexin 1 (ANXA1), a 37 kD protein, originally described as a mediator of glucocorticoid actions, is one of these counter-regulatory mediators 4, 5 . Several pharmacological investigations have reported that ANXA1 inhibits PMN extravasation in models of acute 6 and chronic inflammation 7 , as well as in models of systemic inflammation 8 . These in vivo investigations, coupled with studies of ANXA1 behaviour against human neutrophil activation, have led us to propose the following model: in resting PMN, ANXA1 largely localised within the cytosol 9 , but it can be rapidly mobilised on the cell surface when the PMN adheres to endothelial monolayers 10 . Once on the neutrophil plasma membrane, ANXA1 acts in an autocrine/paracrine fashion to reduce cell extravasation 11 . This model is corroborated by studies with passive immuno-neutralization strategies 12 as well as by more recent investigations with ANXA1 null PMN 13, 14 . In this context, it is worth noting that the anti-migratory effects of ANXA1 have been reproduced by peptides derived from the Nonly.
For personal use at PENN STATE UNIVERSITY on . bloodjournal.hematologylibrary.org From -4 -terminal region, both in vivo 15, 16 as well as in neutrophil/endothelium interactions in static systems in vitro 17, 18 .
A new interest in the field has been generated by the observation that ANXA1 and its Nterminal peptides bind to a specific class of G-protein coupled 7 transmembrane receptors, the formyl-peptide receptors (FPR) 19 . In the mouse this family comprises several putative members, but only three receptor types have been identified in man 20 . Human FPR is the classical receptor for the chemoattractant formyl-Met-Leu-Phe, whereas the related receptor (~70% similarity at the nucleotide level) is termed FPRL-1/ALX indicating that it belongs to the FPR family and that the endogenous anti-inflammatory lipid lipoxin A 4 activates it 20, 21 .
Of interest, human FPRL-1/ALX -like 1 binds also aspirin-triggered A 4 22 and serum amyloid protein A 20 . The third member of the family is FPRL-2, not expressed on neutrophils but on monocytes, has recently shown to bind an endogenous peptide derived from heme binding protein 23 . Using transfected cell systems, ANXA1-derived peptides have been shown to activate human FPR 24 , FPRL-1/ALX 25, 26 and FPRL-2 26 under different circumstances.
However binding data for the full-length protein have been reported only for FPRL-1/ALX 25 , whereas its ability to bind to FPR and FPRL-2 is still a matter of speculation.
The present study was undertaken to determine, for the first time, the effect of ANXA1 and its N-terminal bioactive peptide Ac2-26 on neutrophil-endothelium interactions in vitro under defined flow conditions. Analysis of their efficacy in this system has been complemented by an investigation of their binding and activation of human FPR and FPRL-1/ALX, the only two receptors of the family present on human PMN 20 , using transfected cell systems. The data obtained indicate a dichotomy of behaviour between these two agents and may initiate a only.
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Methods

ANXA1 and other ligands
Human ANXA1 cDNA was cloned into the expression vector pGEX-4T-3 27 prior to addition of 800 µg/ml neomycin (Invitrogen) to select for transfectants, which were subsequently maintained in 400 µg/ml neomycin.
Receptor binding assay
Binding experiments were conducted as previously described 25 . Peptide Ac2-26 was 
Assessment of ERK Activation
Activation of ERK was assessed by western blotting using specific antibodies to detect both 
Data handling and statistical analysis
Flow chamber experiments and western blotting were repeated at least three times. Flow cytometry and receptor binding experiments were performed in duplicate or triplicate and repeated at least three times. Within each set of experiments, where applicable, different blood donors were used for each repetition. Data are reported as mean ± SEM and statistical differences were determined by analysis of variance followed by the Dunnett's test. To gain some mechanistic information on the adhesion molecule(s) responsible for PMN rolling in this experimental setting, the effect of specific neutralising antibodies was tested. 
Results
Effect of annexin 1 and peptide Ac2-26 on neutrophil-endothelium interaction under flow
Effect of annexin 1 and peptide Ac2-26 on neutrophil adhesion molecule expression
Experiments were then performed to determine whether the observed effects of ANXA1 and Ac2-26 observed in the flow chamber were due to a modulation of PMN adhesion molecule expression. To this end, a large concentration range of ANXA1 was tested with the finding that a significant increases in L-selectin expression occurred only at the highest concentrations tested (3 and 10 µM; Figure 3a ). This was different from the effect produced from peptide Ac2-26, which provoked marked shedding of L-selectin; an effect replicated by PMN incubation with an active concentration of PAF (Figure 3a ). Similar differences were also observed with respect to CD11b and PSGL-1 (CD162) levels, with ANXA1 being essentially inactive and peptide Ac 2-26 causing modifications in line with those produced by PAF (Figure 3b (Fig 4a,b) . These values were comparable to previously published data 24, 25 ; similarly, displacement curves from human PMN were in line with those obtained previously 25 . In a representative experiment, peptide and 85% for the concentrations of 1 nM, 10 nM, 100 nM, 1 µM and 10 µM, respectively.
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Discussion
Whereas the effects of ANXA1 and its N-terminal peptide on PMN trafficking have been tested in a variety of experimental animal models of inflammation, little has been done to investigate their effect on human PMN activation. In the present study we have monitored for the first time their effect on PMN-endothelium interaction under defined flow conditions, using an in vitro human system that resembles physiological events occurring in inflammation. Analysis of the properties of ANXA1 and peptide Ac2-26 in this experimental system has led to the unexpected observation that they might be acting through distinct receptors thereby initiating responses in human PMN using different mechanisms.
For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From -14 -The inhibitory role of ANXA1 on the process of leukocyte trafficking has predominantly been studied using a pharmacological approach in the experimental animal. Thus, systemic treatment with human recombinant ANXA1 or peptide Ac2-26 dampens PMN recruitment in different vascular beds and in response to several distinct stimuli 7, 27, 32, 33 , the only exception being the lung 34 . These studies have led to a working model in which exogenous and endogenous ANXA1 acts in an autocrine/paracrine fashion to down-regulate PMN extravasation, and the N-terminal derived peptide Ac2-26 is a genuine pharmacophore of the protein 11 . Much less investigated, though, are the putative effects of these two agents on human neutrophil functions. In an initial study we investigated the effect of peptide Ac2-26
and reported its ability to suppress PMN adhesion to endothelial monolayers 17 . Another group extended these observations, with similar results obtained with the full-length protein as well as a nonapeptide derived from the core region of ANXA1 18 . However, both these studies, employed static assays of PMN adhesion whereas it is now clear that PMN interaction with the endothelium under flow conditions is not only of more relevance for modelling initial inflammatory events 29, 35 but is also crucial to produce appropriate cell activation leading to firm adhesion and emigration 36, 37 .
The seminal study of Walther et al 24 42, 43 , and shown that the L-selectin shedding activity of ANXA1 on purified PMN was mediated by the N-terminal region 42 . It is possible that using purified PMN vs. whole blood might affect the ability of ANXA1 to promote L-selectin shedding.
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